Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets

Cell Chemical Biology

Volumn 23, Issue 12, 2016, Pages 1490-1503

  Knezevic, Claire E ^a,d   Wright, Gabriela ^a   Remsing Rix, Lily L ^a   Kim, Woosuk ^b   Kuenzi, Brent M ^a,c   Luo, Yunting ^a   Watters, January M ^a,c   Koomen, John M ^a   Haura, Eric B ^a   Monteiro, Alvaro N ^a   Radu, Caius ^b   Lawrence, Harshani R ^a   Rix, Uwe ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemical proteomics; H6PD; PARP inhibitor; polypharmacology; target identification; target selectivity

Indexed keywords

CYTARABINE; GEMCITABINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; NIRAPARIB; OLAPARIB; PHOSPHOTRANSFERASE; PROTEOME; RUCAPARIB; TALAZOPARIB; VELIPARIB;

A-549 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HEK293 CELL LINE; HUMAN; HYDROGEN BOND; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; METABOLIC DISORDER; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEOMICS;

EID: 85027933448     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2016.10.011     Document Type: Article

References (55)

1. Andrabi, S.A., Umanah, G.K., Chang, C., Stevens, D.A., Karuppagounder, S.S., Gagne, J.P., Poirier, G.G., Dawson, V.L., Dawson, T.M., Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc. Natl. Acad. Sci. USA 111 (2014), 10209–10214.
2. Antolin, A.A., Mestres, J., Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget 5 (2014), 3023–3028.
3. Augustin, A., Lamerz, J., Meistermann, H., Golling, S., Scheiblich, S., Hermann, J.C., Duchateau-Nguyen, G., Tzouros, M., Avila, D.W., Langen, H., et al. Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines. Mol. Cancer Ther. 12 (2013), 520–529.
4. Banhegyi, G., Csala, M., Benedetti, A., Hexose-6-phosphate dehydrogenase: linking endocrinology and metabolism in the endoplasmic reticulum. J. Mol. Endocrinol. 42 (2009), 283–289.
5. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25 (2007), 1035–1044.
6. Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., Helleday, T., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005), 913–917.
7. Byers, L.A., Wang, J., Nilsson, M.B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y.H., Diao, L., et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2 (2012), 798–811.
8. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2 (2012), 401–404.
9. Chuang, H.C., Kapuriya, N., Kulp, S.K., Chen, C.S., Shapiro, C.L., Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res. Treat. 134 (2012), 649–659.
10. Davis, M.I., Hunt, J.P., Herrgard, S., Ciceri, P., Wodicka, L.M., Pallares, G., Hocker, M., Treiber, D.K., Zarrinkar, P.P., Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29 (2011), 1046–1051.
11. Draper, N., Walker, E.A., Bujalska, I.J., Tomlinson, J.W., Chalder, S.M., Arlt, W., Lavery, G.G., Bedendo, O., Ray, D.W., Laing, I., et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat. Genet. 34 (2003), 434–439.
12. Ekblad, T., Schuler, H., Sirtuins are unaffected by PARP inhibitors containing planar nicotinamide bioisosteres. Chem. Biol. Drug Des. 87 (2016), 478–482.
13. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005), 917–921.
14. Gagne, J.P., Pic, E., Isabelle, M., Krietsch, J., Ethier, C., Paquet, E., Kelly, I., Boutin, M., Moon, K.M., Foster, L.J., et al. Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress. Nucleic Acids Res. 40 (2012), 7788–7805.
15. Galmarini, C.M., Mackey, J.R., Dumontet, C., Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15 (2001), 875–890.
16. Gibson, B.A., Zhang, Y., Jiang, H., Hussey, K.M., Shrimp, J.H., Lin, H., Schwede, F., Yu, Y., Kraus, W.L., Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation. Science 353 (2016), 45–50.
17. Gridling, M., Ficarro, S.B., Breitwieser, F.P., Song, L., Parapatics, K., Colinge, J., Haura, E.B., Marto, J.A., Superti-Furga, G., Bennett, K.L., et al. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics. Mol. Cancer Ther. 13 (2014), 2751–2762.
18. Haura, E.B., Sommers, E., Song, L., Chiappori, A., Becker, A., A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J. Thorac. Oncol. 5 (2010), 1806–1814.
19. Hopkins, T.A., Shi, Y., Rodriguez, L.E., Solomon, L.R., Donawho, C.K., DiGiammarino, E.L., Panchal, S.C., Wilsbacher, J.L., Gao, W., Olson, A.M., et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP Inhibitors. Mol. Cancer Res. 13 (2015), 1465–1477.
20. Jungmichel, S., Rosenthal, F., Altmeyer, M., Lukas, J., Hottiger, M.O., Nielsen, M.L., Proteome-wide identification of poly(ADP-Ribosyl)ation targets in different genotoxic stress responses. Mol. Cell 52 (2013), 272–285.
21. Kaelin, W.G. Jr., The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5 (2005), 689–698.
22. Klaeger, S., Gohlke, B., Perrin, J., Gupta, V., Heinzlmeir, S., Helm, D., Qiao, H., Bergamini, G., Handa, H., Savitski, M.M., et al. Chemical proteomics reveals ferrochelatase as a common off-target of kinase inhibitors. ACS Chem. Biol. 11 (2016), 1245–1254.
23. Laing, R.E., Walter, M.A., Campbell, D.O., Herschman, H.R., Satyamurthy, N., Phelps, M.E., Czernin, J., Witte, O.N., Radu, C.G., Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc. Natl. Acad. Sci. USA 106 (2009), 2847–2852.
24. Lavery, G.G., Walker, E.A., Tiganescu, A., Ride, J.P., Shackleton, C.H., Tomlinson, J.W., Connell, J.M., Ray, D.W., Biason-Lauber, A., Malunowicz, E.M., et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J. Clin. Endocrinol. Metab. 93 (2008), 3827–3832.
25. Lavery, G.G., Walker, E.A., Turan, N., Rogoff, D., Ryder, J.W., Shelton, J.M., Richardson, J.A., Falciani, F., White, P.C., Stewart, P.M., et al. Deletion of hexose-6-phosphate dehydrogenase activates the unfolded protein response pathway and induces skeletal myopathy. J. Biol. Chem. 283 (2008), 8453–8461.
26. Lee, J.M., Ledermann, J.A., Kohn, E.C., PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann. Oncol. 25 (2014), 32–40.
27. Lehtio, L., Jemth, A.S., Collins, R., Loseva, O., Johansson, A., Markova, N., Hammarstrom, M., Flores, A., Holmberg-Schiavone, L., Weigelt, J., et al. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J. Med. Chem. 52 (2009), 3108–3111.
28. McCrudden, C.M., O'Rourke, M.G., Cherry, K.E., Yuen, H.F., O'Rourke, D., Babur, M., Telfer, B.A., Thomas, H.D., Keane, P., Nambirajan, T., et al. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself. PLoS One, 10, 2015, e0118187.
29. Mellacheruvu, D., Wright, Z., Couzens, A.L., Lambert, J.P., St-Denis, N.A., Li, T., Miteva, Y.V., Hauri, S., Sardiu, M.E., Low, T.Y., et al. The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat. Methods 10 (2013), 730–736.
30. Mendes-Pereira, A.M., Martin, S.A., Brough, R., McCarthy, A., Taylor, J.R., Kim, J.S., Waldman, T., Lord, C.J., Ashworth, A., Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1 (2009), 315–322.
31. Menear, K.A., Adcock, C., Boulter, R., Cockcroft, X.L., Copsey, L., Cranston, A., Dillon, K.J., Drzewiecki, J., Garman, S., Gomez, S., et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem. 51 (2008), 6581–6591.
32. Murai, J., Huang, S.Y., Das, B.B., Renaud, A., Zhang, Y., Doroshow, J.H., Ji, J., Takeda, S., Pommier, Y., Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72 (2012), 5588–5599.
33. Murai, J., Huang, S.Y., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J.H., Pommier, Y., Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 13 (2014), 433–443.
34. Murray, J., Thomas, H., Berry, P., Kyle, S., Patterson, M., Jones, C., Los, G., Hostomsky, Z., Plummer, E.R., Boddy, A.V., et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br. J. Cancer 110 (2014), 1977–1984.
35. Narwal, M., Venkannagari, H., Lehtio, L., Structural basis of selective inhibition of human tankyrases. J. Med. Chem. 55 (2012), 1360–1367.
36. Nathanson, D.A., Armijo, A.L., Tom, M., Li, Z., Dimitrova, E., Austin, W.R., Nomme, J., Campbell, D.O., Ta, L., Le, T.M., et al. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. J. Exp. Med. 211 (2014), 473–486.
37. Overington, J.P., Al-Lazikani, B., Hopkins, A.L., How many drug targets are there?. Nat. Rev. Drug Discov. 5 (2006), 993–996.
38. Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, A., McHugh, P., Newell, D., et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14 (2008), 7917–7923.
39. Prasad, R., Williams, J.G., Hou, E.W., Wilson, S.H., Pol beta associated complex and base excision repair factors in mouse fibroblasts. Nucleic Acids Res. 40 (2012), 11571–11582.
40. Remsing Rix, L.L., Kuenzi, B.M., Luo, Y., Remily-Wood, E., Kinose, F., Wright, G., Li, J., Koomen, J.M., Haura, E.B., Lawrence, H.R., et al. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem. Biol. 9 (2014), 353–358.
41. Rix, U., Superti-Furga, G., Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5 (2009), 616–624.
42. Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L.L., Planyavsky, M., Fernbach, N.V., Kaupe, I., Bennett, K.L., Valent, P., Colinge, J., et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110 (2007), 4055–4063.
43. Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann, S.H., Poirier, G.G., PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10 (2010), 293–301.
44. Savitski, M.M., Reinhard, F.B., Franken, H., Werner, T., Savitski, M.F., Eberhard, D., Martinez Molina, D., Jafari, R., Dovega, R.B., Klaeger, S., et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science, 346, 2014, 1255784.
45. Scott, C.L., Swisher, E.M., Kaufmann, S.H., Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J. Clin. Oncol. 33 (2015), 1397–1406.
46. Shen, Y., Rehman, F.L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C.J., Post, L.E., Ashworth, A., BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin. Cancer Res. 19 (2013), 5003–5015.
47. Strom, C.E., Johansson, F., Uhlen, M., Szigyarto, C.A., Erixon, K., Helleday, T., Poly(ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 39 (2011), 3166–3175.
48. Sumi, N.J., Kuenzi, B.M., Knezevic, C.E., Remsing Rix, L.L., Rix, U., Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer. ACS Chem. Biol. 10 (2015), 2680–2686.
49. Tagawa, N., Kubota, S., Kobayashi, Y., Kato, I., Genistein inhibits glucocorticoid amplification in adipose tissue by suppression of 11beta-hydroxysteroid dehydrogenase type 1. Steroids 93 (2015), 77–86.
50. Teo, G., Liu, G., Zhang, J., Nesvizhskii, A.I., Gingras, A.C., Choi, H., SAINTexpress: improvements and additional features in Significance Analysis of INTeractome software. J. Proteomics 100 (2014), 37–43.
51. Tulin, A., Re-evaluating PARP1 inhibitor in cancer. Nat. Biotechnol. 29 (2011), 1078–1079.
52. Wahlberg, E., Karlberg, T., Kouznetsova, E., Markova, N., Macchiarulo, A., Thorsell, A.G., Pol, E., Frostell, A., Ekblad, T., Oncu, D., et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat. Biotechnol. 30 (2012), 283–288.
53. Yang, K.S., Budin, G., Tassa, C., Kister, O., Weissleder, R., Bioorthogonal approach to identify unsuspected drug targets in live cells. Angew. Chem. Int. Ed. Engl. 52 (2013), 10593–10597.
54. Ziegler, S., Pries, V., Hedberg, C., Waldmann, H., Target identification for small bioactive molecules: finding the needle in the haystack. Angew. Chem. Int. Ed. Engl. 52 (2013), 2744–2792.
55. Zybailov, B.L., Florens, L., Washburn, M.P., Quantitative shotgun proteomics using a protease with broad specificity and normalized spectral abundance factors. Mol. Biosyst. 3 (2007), 354–360.